Answers are grounded in this paper and cite their sources.
Greater visit-to-visit variability in atherogenic lipoprotein levels significantly associates with coronary atheroma progression and clinical outcomes, although the association between achieved atherogenic lipoproteins and atheroma progression appears stronger. These data highlight the importance of achieving low and consistent atherogenic lipoprotein levels to promote plaque regression and improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Clark et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: